Shares of Gilead Sciences Inc. GILD inched 0.59% higher to $93.95 Tuesday, on what proved to be an all-around positive ...

Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the ...

Nvidia has dominated the AI narrative in the stock market, captivating investors and the media after soaring 2,190% over the ...

Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...

Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the ...

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.57 which represents a slight increase of $1.48 or 1.62% from the prior close of $91.09. The stock opened at $90.92 and ...

Gilead Sciences has raided Sanofi for its next chief medical officer, luring Dietmar Berger, M.D., Ph.D., away from the ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor ...

At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) revealed that it is developing a ...

Gilead Sciences (GILD) and Terray Therapeutics have entered into a strategic collaboration to discover and develop small ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences (GILD) closed the most recent trading day at $91.09, moving +0.44% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.09%. Elsewhere, the ...